Table 1.
Associations between LIG3 gene polymorphisms and neuroblastoma susceptibility
| Genotype | Cases (N=469) |
Controls (N=998) |
P a | Crude OR (95% CI) |
P | Adjusted OR (95% CI) b |
P b |
|---|---|---|---|---|---|---|---|
| rs1052536 (HWE=0.902) | |||||||
| CC | 224 (47.76) | 479 (48.00) | 1.00 | 1.00 | |||
| CT | 199 (42.43) | 426 (42.69) | 1.00 (0.79-1.26) | 0.993 | 1.00 (0.79-1.26) | 0.993 | |
| TT | 46 (9.81) | 93 (9.32) | 1.06 (0.72-1.56) | 0.775 | 1.06 (0.72-1.56) | 0.773 | |
| Additive | 0.956 | 1.02 (0.86-1.20) | 0.843 | 1.02 (0.86-1.20) | 0.833 | ||
| Dominant | 245 (52.24) | 519 (52.00) | 0.933 | 1.01 (0.81-1.26) | 0.933 | 1.01 (0.81-1.26) | 0.920 |
| Recessive | 423 (90.19) | 905 (90.68) | 0.765 | 1.06 (0.73-1.54) | 0.764 | 1.06 (0.73-1.54) | 0.765 |
| rs4796030 (HWE=0.478) | |||||||
| AA | 144 (30.70) | 307 (30.76) | 1.00 | 1.00 | |||
| AC | 234 (49.89) | 483 (48.40) | 1.03 (0.80-1.33) | 0.802 | 1.04 (0.80-1.33) | 0.790 | |
| CC | 91 (19.40) | 208 (20.84) | 0.93 (0.68-1.28) | 0.666 | 0.93 (0.68-1.28) | 0.668 | |
| Additive | 0.790 | 0.97 (0.83-1.14) | 0.728 | 0.97 (0.83-1.14) | 0.731 | ||
| Dominant | 325 (69.30) | 691 (69.24) | 0.982 | 1.00 (0.79-1.27) | 0.982 | 1.00 (0.79-1.27) | 0.973 |
| Recessive | 378 (80.60) | 790 (79.16) | 0.524 | 0.91 (0.69-1.20) | 0.524 | 0.91 (0.69-1.20) | 0.520 |
| Combine risk genotypes c | |||||||
| 0 | 45 (9.59) | 116 (11.62) | 1.00 | 1.00 | |||
| 1 | 424 (90.41) | 881 (88.28) | 1.24 (0.86-1.78) | 0.245 | 1.24 (0.86-1.79) | 0.242 | |
| 2 | 0 (0.00) | 1 (0.10) | 0.401 | / | 0.981 | / | 0.981 |
| 0 | 45 (9.59) | 116 (11.62) | 1.00 | 1.00 | |||
| 1-2 | 424 (90.41) | 882 (88.38) | 0.246 | 1.24 (0.86-1.78) | 0.247 | 1.24 (0.86-1.79) | 0.244 |
OR, odds ratio; CI, confidence interval.
a χ2 test for genotype distributions between neuroblastoma cases and cancer-free controls.
b Adjusted for age and gender.
c Risk genotypes were rs1052536 TT and rs4796030 AA/AC.